The clinical efficacy of Afatinib 30 mg daily as starting dose may not be inferior to Afatinib 40 mg daily in patients with stage IV lung Adenocarcinoma harboring exon 19 or exon 21 mutations
Abstract Background Afatinib is a second-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI). Compared to cytotoxic chemotherapy, afatinib has been shown to have better efficacy in the treatment of non-small cell lung cancer harboring EGFR mutations. However, 40 mg dai...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2017-12-01
|
| Series: | BMC Pharmacology and Toxicology |
| Subjects: | |
| Online Access: | http://link.springer.com/article/10.1186/s40360-017-0190-1 |
| _version_ | 1830404382086135808 |
|---|---|
| author | Chih-Jen Yang Ming-Ju Tsai Jen-Yu Hung Mei-Hsuan Lee Ying-Ming Tsai Yu-Chen Tsai Jui-Feng Hsu Ta-Chih Liu Ming-Shyan Huang Inn-Wen Chong |
| author_facet | Chih-Jen Yang Ming-Ju Tsai Jen-Yu Hung Mei-Hsuan Lee Ying-Ming Tsai Yu-Chen Tsai Jui-Feng Hsu Ta-Chih Liu Ming-Shyan Huang Inn-Wen Chong |
| author_sort | Chih-Jen Yang |
| collection | DOAJ |
| description | Abstract Background Afatinib is a second-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI). Compared to cytotoxic chemotherapy, afatinib has been shown to have better efficacy in the treatment of non-small cell lung cancer harboring EGFR mutations. However, 40 mg daily as the initial dose is often accompanied by serious adverse drug reactions (ADRs) and 28 to 53.3% of patients required a dose reduction. No previous study has compared the clinical efficacy and ADRs of different initial doses (40 mg vs. 30 mg daily) of afatinib in lung cancer treatment. Methods Patients with stage IV lung adenocarcinoma diagnosed and treated in two Kaohsiung Medical University-affiliated hospitals in Taiwan between May 2014 and August 2016 were identified and followed until December 2016. Demographic characteristics, responses, progression-free survival (PFS), overall survival (OS), and ADRs were recorded. Result A total of 48 patients with stage IV lung adenocarcinoma harboring susceptible EGFR mutations who received afatinib as their first-line therapy were enrolled. Patients using 30 mg daily as the initial dose tended to be older and female and have a smaller body size. The patients using 30 mg of afatinib daily as their initial dose had a similar response rate to those receiving 40 mg daily (76% vs. 95%, p = 0.0862) and the same disease control rate (100% vs. 100%, p = 0.1486). The PFS was similar between the patients receiving 30 mg or 40 mg of afatinib daily (median PFS: 469 vs. 443 days, log-rank p = 0.8418). Patients receiving 30 mg daily had a significantly lower incidence of diarrhea than those using 40 mg daily (41% vs. 100%, p < 0.0001). Conclusion An initial afatinib dose of 30 mg daily had similar response and progression-free survival rates as an initial dose of 40 mg daily, but resulted in fewer serious ADRs in this study. |
| first_indexed | 2024-12-20T17:24:38Z |
| format | Article |
| id | doaj.art-33956710f01642379573e81a16a338be |
| institution | Directory Open Access Journal |
| issn | 2050-6511 |
| language | English |
| last_indexed | 2024-12-20T17:24:38Z |
| publishDate | 2017-12-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Pharmacology and Toxicology |
| spelling | doaj.art-33956710f01642379573e81a16a338be2022-12-21T19:31:37ZengBMCBMC Pharmacology and Toxicology2050-65112017-12-011811810.1186/s40360-017-0190-1The clinical efficacy of Afatinib 30 mg daily as starting dose may not be inferior to Afatinib 40 mg daily in patients with stage IV lung Adenocarcinoma harboring exon 19 or exon 21 mutationsChih-Jen Yang0Ming-Ju Tsai1Jen-Yu Hung2Mei-Hsuan Lee3Ying-Ming Tsai4Yu-Chen Tsai5Jui-Feng Hsu6Ta-Chih Liu7Ming-Shyan Huang8Inn-Wen Chong9Department of Internal Medicine, Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung Medical UniversityDivision of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical UniversityDivision of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical UniversityDivision of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical UniversityDepartment of Internal Medicine, Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung Medical UniversityDivision of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical UniversityDepartment of Internal Medicine, Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung Medical UniversityDivision of Hematology and Oncology, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical UniversityDivision of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical UniversityDivision of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical UniversityAbstract Background Afatinib is a second-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI). Compared to cytotoxic chemotherapy, afatinib has been shown to have better efficacy in the treatment of non-small cell lung cancer harboring EGFR mutations. However, 40 mg daily as the initial dose is often accompanied by serious adverse drug reactions (ADRs) and 28 to 53.3% of patients required a dose reduction. No previous study has compared the clinical efficacy and ADRs of different initial doses (40 mg vs. 30 mg daily) of afatinib in lung cancer treatment. Methods Patients with stage IV lung adenocarcinoma diagnosed and treated in two Kaohsiung Medical University-affiliated hospitals in Taiwan between May 2014 and August 2016 were identified and followed until December 2016. Demographic characteristics, responses, progression-free survival (PFS), overall survival (OS), and ADRs were recorded. Result A total of 48 patients with stage IV lung adenocarcinoma harboring susceptible EGFR mutations who received afatinib as their first-line therapy were enrolled. Patients using 30 mg daily as the initial dose tended to be older and female and have a smaller body size. The patients using 30 mg of afatinib daily as their initial dose had a similar response rate to those receiving 40 mg daily (76% vs. 95%, p = 0.0862) and the same disease control rate (100% vs. 100%, p = 0.1486). The PFS was similar between the patients receiving 30 mg or 40 mg of afatinib daily (median PFS: 469 vs. 443 days, log-rank p = 0.8418). Patients receiving 30 mg daily had a significantly lower incidence of diarrhea than those using 40 mg daily (41% vs. 100%, p < 0.0001). Conclusion An initial afatinib dose of 30 mg daily had similar response and progression-free survival rates as an initial dose of 40 mg daily, but resulted in fewer serious ADRs in this study.http://link.springer.com/article/10.1186/s40360-017-0190-1Lung cancerAdenocarcinomaAfatinibEpidermal growth factor receptorTyrosine kinase inhibitor;diarrheaAdverse drug reaction |
| spellingShingle | Chih-Jen Yang Ming-Ju Tsai Jen-Yu Hung Mei-Hsuan Lee Ying-Ming Tsai Yu-Chen Tsai Jui-Feng Hsu Ta-Chih Liu Ming-Shyan Huang Inn-Wen Chong The clinical efficacy of Afatinib 30 mg daily as starting dose may not be inferior to Afatinib 40 mg daily in patients with stage IV lung Adenocarcinoma harboring exon 19 or exon 21 mutations BMC Pharmacology and Toxicology Lung cancer Adenocarcinoma Afatinib Epidermal growth factor receptor Tyrosine kinase inhibitor;diarrhea Adverse drug reaction |
| title | The clinical efficacy of Afatinib 30 mg daily as starting dose may not be inferior to Afatinib 40 mg daily in patients with stage IV lung Adenocarcinoma harboring exon 19 or exon 21 mutations |
| title_full | The clinical efficacy of Afatinib 30 mg daily as starting dose may not be inferior to Afatinib 40 mg daily in patients with stage IV lung Adenocarcinoma harboring exon 19 or exon 21 mutations |
| title_fullStr | The clinical efficacy of Afatinib 30 mg daily as starting dose may not be inferior to Afatinib 40 mg daily in patients with stage IV lung Adenocarcinoma harboring exon 19 or exon 21 mutations |
| title_full_unstemmed | The clinical efficacy of Afatinib 30 mg daily as starting dose may not be inferior to Afatinib 40 mg daily in patients with stage IV lung Adenocarcinoma harboring exon 19 or exon 21 mutations |
| title_short | The clinical efficacy of Afatinib 30 mg daily as starting dose may not be inferior to Afatinib 40 mg daily in patients with stage IV lung Adenocarcinoma harboring exon 19 or exon 21 mutations |
| title_sort | clinical efficacy of afatinib 30 mg daily as starting dose may not be inferior to afatinib 40 mg daily in patients with stage iv lung adenocarcinoma harboring exon 19 or exon 21 mutations |
| topic | Lung cancer Adenocarcinoma Afatinib Epidermal growth factor receptor Tyrosine kinase inhibitor;diarrhea Adverse drug reaction |
| url | http://link.springer.com/article/10.1186/s40360-017-0190-1 |
| work_keys_str_mv | AT chihjenyang theclinicalefficacyofafatinib30mgdailyasstartingdosemaynotbeinferiortoafatinib40mgdailyinpatientswithstageivlungadenocarcinomaharboringexon19orexon21mutations AT mingjutsai theclinicalefficacyofafatinib30mgdailyasstartingdosemaynotbeinferiortoafatinib40mgdailyinpatientswithstageivlungadenocarcinomaharboringexon19orexon21mutations AT jenyuhung theclinicalefficacyofafatinib30mgdailyasstartingdosemaynotbeinferiortoafatinib40mgdailyinpatientswithstageivlungadenocarcinomaharboringexon19orexon21mutations AT meihsuanlee theclinicalefficacyofafatinib30mgdailyasstartingdosemaynotbeinferiortoafatinib40mgdailyinpatientswithstageivlungadenocarcinomaharboringexon19orexon21mutations AT yingmingtsai theclinicalefficacyofafatinib30mgdailyasstartingdosemaynotbeinferiortoafatinib40mgdailyinpatientswithstageivlungadenocarcinomaharboringexon19orexon21mutations AT yuchentsai theclinicalefficacyofafatinib30mgdailyasstartingdosemaynotbeinferiortoafatinib40mgdailyinpatientswithstageivlungadenocarcinomaharboringexon19orexon21mutations AT juifenghsu theclinicalefficacyofafatinib30mgdailyasstartingdosemaynotbeinferiortoafatinib40mgdailyinpatientswithstageivlungadenocarcinomaharboringexon19orexon21mutations AT tachihliu theclinicalefficacyofafatinib30mgdailyasstartingdosemaynotbeinferiortoafatinib40mgdailyinpatientswithstageivlungadenocarcinomaharboringexon19orexon21mutations AT mingshyanhuang theclinicalefficacyofafatinib30mgdailyasstartingdosemaynotbeinferiortoafatinib40mgdailyinpatientswithstageivlungadenocarcinomaharboringexon19orexon21mutations AT innwenchong theclinicalefficacyofafatinib30mgdailyasstartingdosemaynotbeinferiortoafatinib40mgdailyinpatientswithstageivlungadenocarcinomaharboringexon19orexon21mutations AT chihjenyang clinicalefficacyofafatinib30mgdailyasstartingdosemaynotbeinferiortoafatinib40mgdailyinpatientswithstageivlungadenocarcinomaharboringexon19orexon21mutations AT mingjutsai clinicalefficacyofafatinib30mgdailyasstartingdosemaynotbeinferiortoafatinib40mgdailyinpatientswithstageivlungadenocarcinomaharboringexon19orexon21mutations AT jenyuhung clinicalefficacyofafatinib30mgdailyasstartingdosemaynotbeinferiortoafatinib40mgdailyinpatientswithstageivlungadenocarcinomaharboringexon19orexon21mutations AT meihsuanlee clinicalefficacyofafatinib30mgdailyasstartingdosemaynotbeinferiortoafatinib40mgdailyinpatientswithstageivlungadenocarcinomaharboringexon19orexon21mutations AT yingmingtsai clinicalefficacyofafatinib30mgdailyasstartingdosemaynotbeinferiortoafatinib40mgdailyinpatientswithstageivlungadenocarcinomaharboringexon19orexon21mutations AT yuchentsai clinicalefficacyofafatinib30mgdailyasstartingdosemaynotbeinferiortoafatinib40mgdailyinpatientswithstageivlungadenocarcinomaharboringexon19orexon21mutations AT juifenghsu clinicalefficacyofafatinib30mgdailyasstartingdosemaynotbeinferiortoafatinib40mgdailyinpatientswithstageivlungadenocarcinomaharboringexon19orexon21mutations AT tachihliu clinicalefficacyofafatinib30mgdailyasstartingdosemaynotbeinferiortoafatinib40mgdailyinpatientswithstageivlungadenocarcinomaharboringexon19orexon21mutations AT mingshyanhuang clinicalefficacyofafatinib30mgdailyasstartingdosemaynotbeinferiortoafatinib40mgdailyinpatientswithstageivlungadenocarcinomaharboringexon19orexon21mutations AT innwenchong clinicalefficacyofafatinib30mgdailyasstartingdosemaynotbeinferiortoafatinib40mgdailyinpatientswithstageivlungadenocarcinomaharboringexon19orexon21mutations |